Science has proven extremely successful at quantifying certain risks in healthcare. But when it comes to setting public health policy, including cancer screening recommendations and guidelines, science only goes so far.

The QY Market research study, titled Worldwide Diagnostic Imaging Instrument Market 2016, presents critical information and factual data about the Diagnostic Imaging Instrument market globally, providing an overall statistical study of the Diagnostic Imaging Instrument market on the basis of market drivers, Diagnostic Imaging Instrument Market limitations, and its future prospects. The prevalent global Diagnostic Imaging Instrument trends and opportunities are also taken into consideration in Diagnostic Imaging Instrument industry study.

Researchers from the University of Twente in the Netherlands are currently developing a biopsy robot that they say “combines the best aspects of MRI and ultrasound” to improve the diagnosis of breast cancer and certain muscle diseases.

Not all patients going online to tap the “wisdom of the crowd” for help with difficult diagnoses find what they seek. But a new study shows that some surely do, coming away with medical guidance more helpful than what they got from their own physicians.

Citing concerns over attendee safety, the European Society of Thoracic Imaging (ESTI) has postponed its 2016 annual scientific meeting to an alternate date and time yet to be named.   

In a retrospective comparison of 116 fetal MRI exams—half performed at 3T, half at 1.5T—the higher field strength produced the higher imaging scores. 

A simulation study using two modeling approaches has shown that yearly digital breast cancer screening of U.S. women aged 40 to 74 may stave off 968 breast cancer deaths per 100,000 women screened—but the associated radiation exposure stands to cause 125 cancers leading to 16 deaths in the same cohort.

In a sample group of more than 64,000 elderly women who had mammograms from 1995 to 2009, those who self-selected for annual mammography had lower 10-year breast cancer mortality than those who opted for biennial, irregular or no exams.